Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Oksana Demediuk (NPI 1972599496)

Field	Value
Entity Type	Individual
Organization	Oksana Demediuk
Address	3520 Walton Way Ext
City	Augusta
State	GA
ZIP	30909
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	September 20, 2005

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: Total Medicare revenue is $2.9M while there is no Medicaid billing on file, so the practice’s revenue exposure is concentrated in Medicare reimbursement and drug payments rather than a mix of Medicaid and Medicare. Analysts should treat this profile as Medicare‑driven when assessing payer risk and network negotiations.

Revenue is highly concentrated in a small number of injectable drug codes: the precomputed top 3 codes account for 78.6% of Medicare revenue, with J0178 alone representing 54.4% of total Medicare revenue. That concentration signals that anti‑VEGF/biologic drug administration is the core revenue engine for this provider.

The code mix and top line items indicate a retina‑focused, office‑based intravitreal injection practice: J0178 (aflibercept) has 2.3K claims and $1.6M revenue, J2777 (faricimab) and J3490 (Unclassified drugs) are the other major contributors, and 67028 (intravitreal injection procedure) appears with 1.8K claims and $143.3K revenue. This combination of high‑volume drug J‑codes plus 67028 supports a workflow centered on repeated in‑office injections rather than surgical retina procedures.

Imaging and diagnostic codes are also prominent and relatively high volume for the specialty: 92134 (computerized retinal imaging) shows 2.1K claims, $60K revenue and is described as "notably above typical national volume," suggesting the practice performs frequent OCT imaging to support injection decision‑making and follow‑up. High imaging throughput could drive ancillary revenue and reflects typical retina care patterns.

The provider is using a mix of branded biologics and biosimilars: Q5128 (ranibizumab biosimilar) appears with 788 claims and $171K revenue, Q5124 with 100 claims and $16.5K, and J2778 (ranibizumab) with 467 claims and $84.1K. This code mix indicates adoption of both originator and biosimilar agents, which may affect average drug cost per claim and payer spend comparisons.

J3490 (Unclassified drugs) is a material revenue item with 189 claims, $2115 avg paid/claim and $399.7K revenue (13.9% of Medicare revenue); the high avg paid/claim for an unclassified drug entry suggests significant use of non‑specific drug billing lines that deserve review when reconciling drug costs and ensuring correct coding. Analysts should flag J3490 for clinical/billing validation given its outsized share.

Competitive standing is mixed: for primary injectable codes the provider generally ranks in the upper national percentiles but is described as "typical, unremarkable volume" for those codes (J0178 at the 87th percentile, J3490 at the 87th percentile, J2777 at the 51th percentile), while 92134 is at the 97th percentile and labeled "notably above typical national volume." In aggregate this suggests the provider is a solid regional contributor with particularly high imaging throughput, but not a dominant national outlier for anti‑VEGF administrations.

The NPI has been enumerated since 2005‑09‑20 (~21 years ago), indicating a long tenure which typically corresponds to an established referral base and stable clinical operations. For payers and analysts, that longevity combined with Medicare‑only billing suggests a mature, Medicare‑centric retina practice whose financial metrics will be sensitive to changes in Medicare drug reimbursement and utilization patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

18 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,260	$690	$1.6M
J3490	Unclassified drugs	190	$2,120	$399.7K
J2777	Injection, faricimab‑svoa, 0.1 mg	10,260	$30	$297.5K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	790	$220	$171K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,810	$80	$143.3K
J2778	Injection, ranibizumab, 0.1 mg	470	$180	$84.1K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,140	$30	$60K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	590	$80	$48.6K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	260	$100	$24.9K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	220	$80	$16.6K

Showing 1–10 of 18

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Oksana Demediuk — 5 of 18 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

18 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	5	70	970	$680	$700.6K
J2777	29	40	14,100	$30	$524.3K
J2778	20	30	1,170	$180	$286.2K
Q5128	1	10	390	$220	$98.6K
67028	6	80	720	$90	$71.9K
J3490	1	50	50	$320	$19.8K
92014	292	850	130	$80	$19.7K
99214	1,164	13,640	120	$80	$17.8K
Q5124	1	10	100	$160	$16.5K
99213	3,282	13,360	80	$60	$9.2K

Showing 1–10 of 18

Related Providers

Other providers that share a Tax Identification Number (TIN) with Oksana Demediuk, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Joshua Robinson	MI	Ophthalmology Physician	$3.7M	$0
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Barron Fishburne	SC	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
Jeffrey Gross	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
David Johnson	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
Daniel Will	SC	Retina Specialist (Ophthalmology) Physician	$2.8M	$0
Eugene Long	GA	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Oksana Demediuk, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Faircloth Bakeman Partnership	GA	Oral and Maxillofacial Surgery (Dentist)	$0	$4M
Augusta Obstetrics And Gynecology Specialists, LLC	GA	Obstetrics & Gynecology Physician	$0	$3.7M
Eye Surgery Center Of Augusta, LLC	GA	Ambulatory Surgical Clinic/Center	$3.2M	$0
Pediatricare Pm	GA	Pediatrics Physician	$0	$2.8M
Doctors Hospital Of Augusta LLC	GA	General Acute Care Hospital	$0	$2.2M
Joseph M Still Burn Centers, Inc	GA	Specialist	$0	$2M
Ranjit Dhaliwal	GA	Retina Specialist (Ophthalmology) Physician	$1.9M	$0
Dennis Marcus	GA	Ophthalmology Physician	$1.8M	$0
David Squires	GA	Hematology & Oncology Physician	$1.6M	$0
Aos Surgery Center LLC	GA	Ambulatory Surgical Clinic/Center	$1.1M	$0

Oksana Demediuk — Billing Profile & Reimbursement Data

Sign up for Oksana Demediuk — Billing Profile & Reimbursement Data policy alerts

Oksana Demediuk — Billing Profile & Reimbursement Data

Sign up for Oksana Demediuk — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References